Reports Q1 revenue $15M, consensus $2.14M. “This was a productive quarter for Centessa (CNTA), marked by steady progress across our OX2R agonist pipeline,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. “The orexin pathway represents a promising new frontier in neuroscience, with the potential to address not only sleep-wake disorders, but also excessive daytime sleepiness in a broad spectrum of neurological, neurodegenerative and neuropsychiatric disorders, as well as impaired attention, cognitive deficits and fatigue.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz
- Uber downgraded, Rockwell Automation upgraded: Wall Street’s top analyst calls
- Centessa initiated with a Buy at Chardan
- Centessa Pharmaceuticals’ ORX750: Promising Developments and Buy Rating by David Risinger
- Centessa initiated with an Overweight at Piper Sandler
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue